Lencioni 2010 mRECIST for typical intrahepatic HCC target lesions. First-match: PD if new_lesion or a 20% or greater viable-sum increase vs nadir; else CR if arterial enhancement disappeared in all targets; else PR if a 30% or greater viable-sum decrease vs baseline; else SD. Caller-assigned flags; magent does not read imaging. Not a medical device, not a diagnosis, not RECIST 1.1, not EASL necrosis-only, not the 2019 Llovet +5 mm PD refinement, and not nontarget-only overall response.

Payment Options